Ticker >

Mercury Laboratories share price

Mercury Laboratories Ltd.

BSE: 538964 SECTOR: Pharmaceuticals & Drugs  9119   17   0

894.00
0 0
BSE: 26 Apr 04:01 PM

Price Summary

Today's High

₹ 899

Today's Low

₹ 860.45

52 Week High

₹ 1303

52 Week Low

₹ 535.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

107.28 Cr.

Enterprise Value

105.33 Cr.

No. of Shares

0.12 Cr.

P/E

26.1

P/B

2.19

Face Value

₹ 10

Div. Yield

0.39 %

Book Value (TTM)

₹  407.78

CASH

7.32 Cr.

DEBT

5.36 Cr.

Promoter Holding

73.66 %

EPS (TTM)

₹  34.26

Sales Growth

30.06%

ROE

12.98 %

ROCE

16.29%

Profit Growth

56.62 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year30.06%
3 Year9.57%
5 Year7.75%

Profit Growth

1 Year56.62%
3 Year20%
5 Year22.61%

ROE%

1 Year12.98%
3 Year12.57%
5 Year11.71%

ROCE %

1 Year16.29%
3 Year16.37%
5 Year15.23%

Debt/Equity

0.1176

Price to Cash Flow

43.74

Interest Cover Ratio

21.7043382149765

CFO/PAT (5 Yr. Avg.)

1.29347183967661

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 73.66 0
Dec 2023 73.66 0
Sep 2023 73.66 0
Jun 2023 73.66 0
Mar 2023 73.66 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 20.0039156954102% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 21.7043382149765.
  • Company’s PEG ratio is 0.460860054846759.
  • The company has an efficient Cash Conversion Cycle of -2.75758888243359 days.
  • Company has a healthy liquidity position with current ratio of 2.53884783482061.
  • The company has a good cash flow management; CFO/PAT stands at 1.29347183967661.
  • The company has a high promoter holding of 73.66%.

 Limitations

  • The company has shown a poor revenue growth of 9.56935911300678% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 16.23 19.43 18.32 22.76 17.12
Total Expenditure 15.65 18.39 16.66 20.27 14.89
Operating Profit 0.58 1.04 1.66 2.49 2.23
Other Income 0.58 0.43 0.15 0.36 0.18
Interest 0.08 0.1 0.08 0.11 0.1
Depreciation 0.63 0.62 0.68 0.71 0.72
Exceptional Items 0 0.05 0 0 0
Profit Before Tax 0.45 0.8 1.06 2.03 1.59
Tax -0.16 0.43 0.06 0.52 0.35
Profit After Tax 0.61 0.37 1 1.51 1.24
Adjusted EPS (Rs) 5.05 3.06 8.33 12.57 10.3

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 55.52 57.27 68.6 57.92 75.33
Total Expenditure 49.8 51.1 59.01 50.93 66.76
Operating Profit 5.72 6.17 9.59 6.99 8.57
Other Income 1.04 0.85 0.88 0.82 1.72
Interest 1.09 0.82 0.64 0.45 0.36
Depreciation 1.63 1.87 1.92 2.45 2.48
Exceptional Items 0 0 0 0.13 0.05
Profit Before Tax 4.05 4.33 7.91 5.03 7.49
Tax 1.21 1.1 2.57 1.47 1.91
Net Profit 2.84 3.23 5.34 3.56 5.58
Adjusted EPS (Rs.) 23.63 26.9 44.48 29.68 46.49

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 1.2 1.2 1.2 1.2 1.2
Total Reserves 27.77 30.78 35.69 39.11 44.43
Borrowings 8.5 6.33 6.24 2.49 2.42
Other N/C liabilities 2.91 2.93 3.4 3.89 3.1
Current liabilities 16.92 15.07 18.83 15.75 16.43
Total Liabilities 57.3 56.3 65.37 62.43 67.58
Assets
Net Block 24.39 23.66 26.36 25.82 24.26
Capital WIP 0 0 0 0 0.13
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.01 0.01
Loans & Advances 0 0 0 0 0
Other N/C Assets 1.01 1.12 1.21 1.39 1.47
Current Assets 31.9 31.51 37.8 35.22 41.71
Total Assets 57.3 56.3 65.37 62.43 67.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 4.05 4.33 7.91 5.03 7.44
Adjustment 2.72 2.69 2.56 2.88 2.85
Changes in Assets & Liabilities -0.52 -0.3 -0.89 -0.8 -6.73
Tax Paid -1.03 -1.23 -1.37 -1.91 -1.1
Operating Cash Flow 5.22 5.49 8.21 5.19 2.45
Investing Cash Flow -4.99 -1.14 -4.62 -1.89 -1.06
Financing Cash Flow -2.54 -3.33 -1.24 -1.23 -1.01
Net Cash Flow -2.31 1.02 2.36 2.07 0.38

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 73.66 73.66 73.66 73.66 73.66
adit dilipbhai shah 1.29 1.29 1.29 1.29 1.29
bimal ramanlal shah 1.17 1.17 1.17 1.17 1.17
dilip ramanlal shah - 7.07 7.07 7.07 7.07
janki rajendra shah - 8.67 8.67 8.67 8.67
kaumudini rajendra shah... - 1.76 1.76 1.76 1.76
kishoriben dilip shah - 0.28 0.28 0.28 0.28
paresh ramanlal shah 1.97 1.97 1.97 1.97 1.97
parulben kiranbhai laliwa... 1.02 1.02 1.02 1.02 1.02
rajendra ramanlal shah - 7.14 7.14 7.14 7.14
shah dilip ramanlal huf... - 25.88 25.88 25.88 25.88
shah rajendra ramanlal ... - 17.42 17.42 17.42 17.42
dilip ramanlal shah 7.07 - - - -
janki rajendra shah 8.67 - - - -
kaumudini rajendra shah 1.76 - - - -
kishoriben dilip shah 0.28 - - - -
rajendra ramanlal shah 7.14 - - - -
shah dilip ramanlal huf 25.88 - - - -
shah rajendra ramanlal hu... 17.42 - - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 26.34 26.34 26.34 26.34 26.34
bharati bharat dattani 1.23 1.64 1.64 1.64 1.64
investor education and pr... - 5.92 5.92 6.01 6.01
ketan babulal shah 2.25 1.45 1.45 1.40 1.23
rajeshri k shah 2.20 2.20 2.20 2.20 2.20
sharad kanayalal shah - 1.11 1.11 1.11 1.11
llp - - 0.05 - -
investor education and pr... 5.92 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Mercury Laboratories - Quaterly Results12 Feb 2024, 2:33PM Mercury Laboratories - Quaterly Results12 Feb 2024, 2:33PM Mercury Laboratories - Quaterly Results12 Feb 2024, 2:33PM Mercury Laboratories informs about loss of share certificates11 Jan 2024, 11:09AM Mercury Laboratories informs about compliances-certificate6 Jan 2024, 12:31PM Mercury Laboratories informs about closure of trading window26 Sep 2023, 10:53AM Mercury Laboratories informs about loss of share certificate20 Sep 2023, 2:28PM Mercury Laboratories informs about newspaper cuttings2 Sep 2023, 3:33PM Mercury Laboratories - Quaterly Results5 Aug 2023, 9:16PM Mercury Laboratories informs about loss of share certificate4 Jul 2023, 10:50AM Mercury Laboratories informs about issue of duplicate share certificate26 May 2023, 1:11PM Mercury Laboratories informs about newspaper cuttings8 May 2023, 12:43PM Mercury Laboratories - Quaterly Results5 May 2023, 5:24PM Mercury Laboratories - Quaterly Results5 May 2023, 5:24PM Mercury Laboratories - Quaterly Results5 May 2023, 5:24PM Mercury Laboratories informs about certificate6 Apr 2023, 12:37PM Mercury Laboratories informs about issue of duplicate certificate21 Mar 2023, 2:38PM Mercury Laboratories informs about loss of share certificate1 Nov 2022, 4:43PM Mercury Laboratories informs about scrutinizer's report28 Sep 2022, 5:12PM Mercury Laboratories informs about closure of trading window 27 Sep 2022, 5:14PM Mercury Laboratories - Quaterly Results9 Aug 2022, 8:18PM Mercury Laboratories - Quaterly Results9 Aug 2022, 8:18PM Mercury Laboratories informs about certificate 6 Jul 2022, 4:44PM Mercury Laboratories - Quaterly Results31 Jan 2022, 6:55PM Mercury Laboratories - Quaterly Results31 Jan 2022, 6:55PM Mercury Laboratories informs about resignation of CS21 Jan 2022, 2:56PM Mercury Laboratories informs about certificate4 Jan 2022, 4:55PM Mercury Laboratories informs about issuance of duplicate share certificate30 Dec 2021, 4:04PM Mercury Laboratories informs about stop transfer request7 Dec 2021, 12:18PM Mercury Laboratories informs about stop transfer request25 Nov 2021, 12:59PM Mercury Laboratories informs about press release23 Oct 2021, 3:57PM Mercury Laboratories informs about stop transfer intimation8 Oct 2021, 3:49PM Mercury Laboratories informs about newspaper publication13 Feb 2021, 11:10AM Mercury Laboratories informs about disclosure21 Nov 2020, 3:43PM

Mercury Laboratories Stock Price Analysis and Quick Research Report. Is Mercury Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mercury Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Mercury Laboratories cash from the operating activity was Rs 2.4524 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mercury Laboratories has a Debt to Equity ratio of 0.1176 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mercury Laboratories , the EPS growth was 56.624273561863 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mercury Laboratories has OPM of 11.3767145381151 % which is a bad sign for profitability.
     
  • ROE: Mercury Laboratories have a average ROE of 12.9836761481854 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Mercury Laboratories is Rs 894. One can use valuation calculators of ticker to know if Mercury Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Mercury Laboratories
X